In the world of value investing, not all that is gold glitters… like Ohio-based OurPet’s Company, for example. OurPet’s Company (OTCQX: OPCO) is a leading proprietary pet supply company that designs, produces, and markets a broad line of innovative, high-quality accessory and consumable pet products under the OurPets® and Pet Zone® brands in the U.S. and international markets. Its yearly revenues have been rising at a steady clip since its inception over 20 years ago and so, too, have its profits. Yet OPCO’s valuation is way below what you might expect. Could this be a case of investors eschewing value because they don’t like the packaging?

No, you may argue. Investors are rational. They make decisions that maximize utility. The rational investor will base his decision on expected returns. Yet, we know now that that is not entirely true. Despite our claims to be rational, we demonstrate a great deal of ‘risk aversion’. We don’t like to lose. We will play it safe because the pain of losing a dollar is greater than the pleasure of finding one.

However, if losing money causes pain, why then do we gamble? Several explanations have been offered. It may be that gamblers are a naughty subset of the population who, unlike their more mature brethren, are decidedly irrational. It may be that our attitudes to risk change with mood. On days when our world looks bright, we are prepared to take more risks than when things don’t look so good. Perhaps, gambling is seen more as entertainment. We would like to win, but if we don’t, at least we had a good time. Or is it because of all the idiosyncrasies that make us human? It isn’t rational, for example, to sacrifice your life to save a stranger. Yet, as ‘The Man in the Water’ (http://dtn.fm/t6Lrk) has shown us, we each have the capacity to do just that.

So investors like glamour. If we say we’re invested early in Facebook or Google, wouldn’t we be regarded as savants? Isn’t that the way Warren Buffet works?

Irony aside, Buffet’s success is based on ‘value investing’. He famously said, “Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.” True value investing means picking up a bargain, companies whose stock prices don’t reflect their fundamental worth. In other words, buy it when it’s on sale.

OPCO is one such company. It prides itself on adaptability. CEO Dr. Steve Tsengas has remarked that one of the main rationales behind the founding of OurPet’s Company in 1994 was the lack of innovation in the pet industry at that time. In fact, so intent on the knowledge-based aspect of the enterprise were its co-founders, Dr. Steve Tsengas and Dean Tsengas, that they decided to focus on generating new and improved solutions for pet owners and ways of getting product to market rather than manufacturing. So, on the one hand, OurPet’s Company concentrates on innovation and design, and, on the other, on marketing and distributing its product line.

The company is focused on high-growth categories in the non-food segment of the pet products market. Healthy feeding/storage systems (http://dtn.fm/3GFrs) represent a $100 million a year market. Feline waste and odor control (http://dtn.fm/3eqBo) is a $250 million a year market. And the interactive cat and dog toys/accessories segment (http://dtn.fm/n4VDL) is a whopping $1 billion a year market.

OPCO has been growing 50 percent faster than the industry rate. With a P/E ratio that has ranged between 12.5 and 14.5, OPCO is definitely a bargain buy.

For more information, visit the company’s website at www.OurPets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Mobile payments have been increasingly adopted since the launch of this new technology back in 2015. By the end of 2016, mobile payments are expected to reach up to $180 billion, and, according to a report entitled ‘Mobile Payments Convergence: Opportunities at the Intersection of In-person, Online and P2P Payments’ (http://nnw.fm/obqQ9), the number of people using mobile wallets in the last 30 days has grown from 12% to nearly one in four people in 2016, approximately 40 million people in the U.S. Experts expect this type of payment to reach a huge $410.5 billion by the end of 2020. So what is shaping the future of mobile payments for 2017?

With new mobile applications and payment wallets inundating the mobile world, consumers are valuing the added simplicity and convenience of storing their card details on their devices. 2017 is said to be the year for ‘invisible payments’. This means that mobile devices are allowing us to become closer to acquiring a seamless in-store experience where initialization and authentication are no longer a concern, but it’s not just about making the payment process easier for consumers.

With ‘tap and go’ payments becoming more and more popular, customers expect this service to be available to them. As a result, simply paying via mobile is no longer the key driver for adoption of this relatively new payment method. The focus for mobile payments “is shifting from changing the payments process into a ‘buying experience’,” according to Mobile Payments Today (http://nnw.fm/Y4ktf). With big data readily available to merchants, customers are valuing specific, intelligent value-added services, some of which include gifts, rewards, loyalty points, and coupons.

Unified Payments, a TOT Group company owned by Net Element, Inc. (NASDAQ: NETE), which provides seamless and secure mobile payment acceptance without the investment in expensive and complicated hardware or services, offers integrated loyalty card solutions that allow merchants to boost sales and increase customer loyalty with personalized incentives. The company works on the basis that customers appreciate being rewarded and earning something back for their loyalty.

The NETE subsidiary offers registration and reporting solutions that allow merchants to retrieve valuable demographic information to improve their marketing initiatives by targeting their consumers with personalized rewards. The company is in-line with the 2017 predictions of offering customers experience-based payment solutions, and does so by giving its clients services with versatile and flexible features that directly target and identify existing customer trends.

For more information, visit the company’s website at www.NetElement.com

Before the opening bell, Monaker Group, Inc. (OTCQB: MKGI), a technology-driven travel company focused primarily on the alternative lodging rental (ALR) market, released a shareholder update outlining its progress throughout 2016, as well as its strategic objectives for the coming year. Some key highlights detailed in this morning’s update include:

• Completion of the company’s proprietary booking engine, which now conforms to all online travel industry standards to allow for easy business to business integration
• Procurement of an extensive collection of rental properties that currently includes over one million lodging options offering ‘real-time’ bookings and more than two million ALR properties
• Anticipated launch of NextTrip.com consumer platform in January 2017 alongside roll-out of business travel partners
• Release of new NextTrip mobile app for both Android and iOS scheduled for the end of January 2017

In addition to a brief overview of the company’s recent progress, this morning’s update included a letter to shareholders from Bill Kerby, chairman and chief executive officer of Monaker Group. After reflecting on the company’s progress during 2016 – including the buildout of its proprietary Monaker Booking Engine (MBE) and ‘plug and play’ application program interface (API), entry into contracts with lodging vendors for roughly two million rental properties and the elimination of over $10 million of debt to effectively strengthen its balance sheet – Kerby turned his attention toward Monaker Group’s future in the rapidly expanding ALR industry, which is on course to reach $169 billion by 2019.

“As the year draws to a close, we can confirm that we expect to launch our alternative lodging rental (ALR) business in January 2017,” Kerby stated in the news release. “This business will have two components. The first is our proprietary Monaker Booking Engine (MBE), which will allow both business travel partners and consumers to access our lodging products. Our other offering, NextTrip.com, is a direct-to-consumer platform that for the first time will provide real-time alternative lodging reservations that include access to all major mainstream travel products and services.”

Kerby and the Monaker Group management team expect both the MBE business solution and the NextTrip consumer platform to be “true game changers in the ALR industry” as a result of their focus on allowing for ‘real-time’ booking. Despite the rising popularity of ALR platforms such as Airbnb, most properties listed through these sites require approval from property owners to confirm bookings. This mechanic has, to this point, limited the integration of ALR listings into popular online travel agencies’ (OTA) service platforms. This issue, combined with a lack of ALR platforms that offer additional mainstream travel services such as flights, rental cars and tour packages, has created a market opportunity that Monaker Group intends to address in the coming months.

“NextTrip will solve both these issues, and, along with our MBE platform, should commence transactional business next month,” Kerby added. “The NextTrip platform has been designed to allow individuals and groups to search, share, converse and recommend vacation destinations, and earn instant “cash back” rewards when they book and contribute to the site… With such rich features, we expect that MBE and NextTrip will appeal to a far greater number of travelers and wholesale travel providers than any other ALR service — and help generate significant booking revenue for Monaker in 2017.”

For more information, visit www.MonakerGroup.com

CytoDyn Inc. (OTCQB: CYDY) is entering a Phase 3 clinical trial with its leading product candidate, PRO 140, and the Washington-based biotech is showing a lot of progress nearing major milestones. PRO 140 is a viral-entry inhibitor, a new class of HIV/AIDS therapies that work by blocking the entry of the human immunodeficiency virus (HIV) to healthy cells. PRO 140 is presently at the Phase 3 clinical trial stage. For the millions worldwide with HIV/AIDS, PRO 140 could offer the promise of a more robust bodyguard from further viral insult with potentially fewer side effects and hardly any toxicity.

HIV, like many other dangerous viruses, has a formidable ability to reproduce itself. The virus will invade an immune system cell and employ that cell’s reproductive machinery to make copies of itself, often killing the host cell in the process. New viral particles then emerge from the host and go on to infect other cells.

Many of the current AIDS therapies slow HIV replication by inhibiting viral enzymes within cells already affected by HIV. However, a new class of drugs, known as viral entry inhibitors, is designed to protect healthy cells from HIV infection by blocking early steps in the viral life cycle.

HIV infection occurs when the virus gains entry to two ‘doorways’ or receptors on the cell surface. These are the CD4 receptor and the co-receptor CCR5. The GP120 protein of HIV first attaches to the CD4 receptor on the cell membrane and then is able to bind to the co-receptor CCR5. At that point, the chips are down. The membranes of the virus and the immune cell fuse, and genetic material from HIV enters the cell.

PRO 140 works by attaching to the same portion of the CCR5 co-receptor to which HIV normally binds. The PRO 140 monoclonal antibodies physically block the HIV from attaching to the CCR5 co-receptor and arrest the completion of the second step in the entry process. The HIV is, consequently, rendered ineffective.

The approach taken by PRO 140 has a distinct advantage over other therapies. The normal function of CCR5 is to bind chemokines, molecules that regulate inflammation. Other HIV drugs that target CCR5 interact with the pocket of the receptor and thereby inhibit binding of both HIV and chemokines, which may have a number of adverse consequences because of the disruption of the chemokine inflammatory response. However, PRO 140 blocks HIV yet permits normal chemokine binding leading to potentially less side effects.

Early clinical testing indicates that PRO 140’s half-life contributes to the masking of CCR5 receptors for up to two months. Thus, infrequent dosing with PRO 140 may be possible compared to small molecule drugs, which require daily dosing.

In addition, being an antibody and not a synthetic drug means that PRO 140 will, most likely, have fewer issues with toxicity. Previous short and long-term trials have shown that PRO 140 is less likely to induce the development of resistant viruses.

Earlier this month, CytoDyn Inc. announced that several patients had been treated in the first single-agent maintenance therapy, Phase 3 (instead of today’s standard of care of at least three agents) in virally suppressed subjects with HIV. PRO 140 is considered one of the most advanced experimental monoclonal antibodies for HIV treatment and has been used in more than 140 HIV-infected patients in placebo controlled and open label FDA-approved clinical trials. The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and being designated a “fast track” product candidate by the FDA.

CytoDyn is a biotechnology company focused on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection.

For more information, visit www.CytoDyn.com

Moxian, Inc. (NASDAQ: MOXC), a China-based company in the business of providing social media-based marketing and promotion platforms to merchants to help them grow their business, continues to show a thorough understanding of China’s online-to-offline (O2O) and social media market demographics. Although it is hard to establish where China’s O2O market stands, O2O in China covers all kinds of services that are offered by brick-and-mortar establishments.

Unlike in the U.S. or Europe, where O2O is often considered to be items purchased online and picked up at a store, in China O2O includes a range of categories. O2O in China takes into account all things travel, accommodation, transport, making dinner reservations, booking medical appointments, and virtually any services that are ordered or booked online but paid for at point of service.

With this mind, who is the primary demographic for China’s O2O market? Although the O2O markets in China, the U.S., and Europe are significantly different, this is largely due to the fact that payments in China are far more likely to be made via a mobile device, according to eMarketer (http://nnw.fm/vzE0B). In addition, the typical buyer in China is likely to be less than 40 years old and live in one of the country’s larger cities.

According to Make a Website Hub (http://nnw.fm/m1FZg), this is also the demographic in China that is most active on social media. 30% of social media users are said to be between the ages of 26 and 30 years, with another 21% of social media users between 31 and 35. With over 650 million social networking users and 400 million of these using mobile to access these social media platforms, it is no wonder that Moxian is making strides in both the O2O and social media marketing industries.

The company has two primary products, Moxian+ User app and Moxian+ Business app.These apps are multi-channel social commerce platforms that allow merchants and consumers to better interact with one another. Moxian+ User app is made up of the Moxian proprietary virtual currency, social networking, a redemption center sponsored by Moxian merchants, and a game center. Moxian+ Business app comes with a built in Social Customer Relationship Management tool where merchants are able to set up a store on the Moxian platform and push promotions through various mediums. The application also allows merchants to respond to customer enquiries through instant messaging, as well as to list items, process orders, and receive reports and analytical insights.

With China’s O2O market demographic showing a strong resemblance to its social media demographic, Moxian, Inc. is able to capitalize on both markets. The company achieved an important uplisting to the NASDAQ on November 15, 2016. This, combined with its new relationship with Beijing Chinaums, a subsidiary of China UnionPay that creates safer and more convenient payment options, allows Moxian to launch the Moxian+ User app on a commercial level by accessing the millions of merchants and users who currently use Chinaums proprietary payment technologies.

For more information, visit the company’s website at www.Moxian.com

CytoDyn Inc. (OTCQB: CYDY) is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection.

Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn’s lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection.

PRO 140 belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral infection. The candidate has been used in more than 200 HIV-infected patients in placebo-controlled and open label FDA-approved clinical trials; has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects; and is designated a “fast track” product candidate by the FDA.

The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially hardly any side effects or toxicity and less frequent dosing requirements, as compared to daily drug therapies currently in use. CytoDyn has received FDA clearance for and currently has two Phase 3 clinical trials underway. The company’s first Phase 3 trial is a pivotal trial with PRO 140 in combination with current standard-of-care antiretroviral therapy (ART) for highly treatment-experienced patients with HIV. This 25-week trial involves only 30 patients with a primary endpoint of just one week of efficacy and the company expects to report primary endpoint results as early as the first quarter of 2017.

The company’s other Phase 3 trial is with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. This multicenter, open-label trial is now enrolling 300 patients prequalified with CCR5-tropic HIV-1 infection who are clinically stable on standard-of-care highly active antiretroviral therapy (HAART). The objective of the trial is to assess the efficacy, safety and tolerability of PRO 140 as a long-acting, single-agent maintenance therapy for the chronic suppression of HIV. Patients enrolled in the trial will be shifted from daily HAART regimens to weekly PRO 140 subcutaneous injections for 48 weeks. This trial protocol is nearly a duplicate of the Phase 2b monotherapy trial, which is ongoing with an extension study that supports a group of patients who have maintained viral suppression for over two years and is continuing.

Additionally, the company has underway a Phase 2 trial to evaluate PRO 140 for Graft vs. Host Disease (GvHD) in a 100-day study involving 60 patients. GvHD is a life-threatening complication for cancer patients undergoing stem cell transplants. This trial will evaluate the safety and efficacy of PRO 140 for prophylaxis of acute GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem-cell transplantation.

CytoDyn operates under the guidance of a highly qualified management team and advisors with experience in a wide range of complementary skillsets, including business development, mechanical engineering, life sciences and biotech, manufacturing and clinical development, IP asset development, biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs and more. Additionally, CytoDyn has established relationships with world-class HIV experts who advise on the company’s trial designs.

For more information, visit www.CytoDyn.com

Rennova Health, Inc. (NASDAQ: RNVA, RNVAX), a vertically integrated public holding company serving the health care sector, focuses on offering comprehensive single-source solutions to health care providers ranging from diagnostic laboratory testing to technology solutions, revenue cycle management and financial and billing services. With a declared goal of creating efficient, innovative and empowering solutions, the company is dedicated to putting the needs of health care providers and their patients at the center of everything it does.

The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting better treatment outcomes, increasing patient care efficiency and optimizing revenue streams. Available individually or as a package, these industry-leading supportive software and diagnostics solutions and services work together to empower customers and help shape the next generation of health care.

The diagnostics testing solutions include highly complex clinical, toxicology and esoteric laboratory services, offered via Rennova Health’s subsidiary, Medytox Diagnostics, and its five labs located strategically across the country. These laboratories offer specialized services of urine drug testing for prescription medication, abuse drugs and pain medication, as well as toxicology, clinical chemistry, hematology, serology, immunology and esoteric testing services such as neurotransmitter tests. The testing and sampling process uses the company’s proprietary StableSpot™ methodology.

The company currently has an active customer base with 139 clients and possesses Medicaid licenses in a total of 28 states. Also part of its clinical lab operations segment, Rennova Health recently initiated the acquisition of various assets of a rural clinical access hospital that filed for Chapter 11 bankruptcy. The acquisition process is to be completed early next year, with the hospital and its laboratory likely back in operation in the third quarter of 2017. Another major acquisition the company plans is that of Genomics, Inc., a biomedical diagnostics company that offers personalized medicine via DNA-guided management. Genomics uses a patented combination of genes and a proprietary platform that correlates gene and physiological variability to come up with ideal medication for pain, diabetes, mental illness and heart disease.

Another essential component of Rennova’s comprehensive solutions offering is health care technology. The company’s integrated software solutions include both specialized applications and simplified technologies for electronic health records, an advanced laboratory information management system and a reporting application designed to help streamline diagnostic laboratory testing, as well as information solutions for precision oncology. The company launched an electronic health records service in the substance abuse sector in the last quarter of 2015 and currently has approximately 100 EHR clients across all verticals.

As for revenue cycle management services, Rennova’s in-house medical billing services solution, Medical Billing Choices, offers a customer-centered workflow designed to minimize errors, streamline customers’ billing cycles and maximize cash flow by expediting tasks such as insurance eligibility checks, claims submissions, and payment collecting. The company launched a specialized medical billing division for substance abuse facilities in the third quarter of the year and currently has approximately 20 facilities as customers.

Rennova also offers financial service solutions to health care providers, designed to help them maintain positive cash flows and overcome any income gaps cause by slow-to-pay customers. From special loans collaterized by accounts receivable to acquisitions of qualifying accounts receivable at a discounted rate, the company offers a wealth of financial solutions tailored to every customer.

For 2017 as well as long term, Rennova Health has plans to create and maintain a sustainable relationship with its customers, to grow revenue and provide added value to its shareholders by increasing and diversifying its diagnostics business, offering improved supportive software solutions and exploring new ways to improve provider and patient outcomes for various diagnostics, including cancer and diabetes. The company’s main target markets at the moment are pain management and drug and alcohol rehabilitation.

For more information, visit www.RennovaHealth.com

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future.

To view this week’s program, visit www.MoneyTV.net

In the interview, Greg Lambrecht, chief executive officer of Singlepoint, commented on the recent movement of the company’s stock, which has recorded above-average volume throughout much of the past two months. On November 4, in particular, Singlepoint’s volume climbed to 22.6 million. For comparison, the company’s average 30-day volume prior to this spike was roughly 4.35 million, according to OTC Markets. Singlepoint’s price per share recorded a similar spike in mid-November.

“We’ve had enormous response from funders, not only in New York but across the country, that are interested in investing in Singlepoint and also interested in helping us with some of our acquisitions,” Lambrecht stated in reference to the company’s recent volume. “We are in the process of looking at a couple of different funding deals and a couple of different acquisitions. It’s a very exciting time right now.”

One driver behind rising investor interest surrounding Singlepoint could be its ongoing forays into the legalized cannabis industry. In early November, the company announced plans to reawaken its SingleSeed subsidiary in order to gain access to the domestic cannabis market, which is projected to climb to $50 billion by 2026, according to data from financial services firm Cowen and Co. In line with these efforts, Singlepoint has recently turned its attention toward broadening its presence in the nation’s cannabis markets ahead of an expected resolution to the industry’s long-standing banking problem.

“One of the things we’re doing, we’re spending some money on really making our SingleSeed website live. That’s SingleSeed.com, and it is specifically set up for dispensaries,” Lambrecht told host Donald Baillargeon. “We’re turning that on to allow people to go in and sign one of our agreements and start to get our text message marketing, which is legal now, and sign up to get a terminal when it’s opened up.”

Lambrecht concluded the MoneyTV interview by taking a look at the current regulatory environment surrounding the cannabis industry. With President-elect Donald Trump having previously suggested plans to leave the regulation of recreational marijuana in the hands of individual states, Lambrecht predicts that it’s only a matter of time before a decision is made to give legal cannabis operations access to financial institutions and electronic payment solutions.

“A congressman from California has already written the Trump administration asking for a meeting,” Lambrecht concluded. “Basically, he’s saying, ‘Hey, California is opened up. These dispensaries need to have a bank account.’ So that, with Florida and Massachusetts, I think the pendulum has swung to where they’re going to let these dispensaries have bank accounts. When that happens, that’s going to be very exciting for Singlepoint.”

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

The increasing levels of solid waste generated in the U.S. each year is drawing attention from lawmakers, and strategies are being implemented on every level to address the issue. The U.S. Department of Agriculture (USDA) is taking steps (http://dtn.fm/tKM4H) to tap into the minds of state and local government entities, academic institutions, and private non-profit organizations by making available Solid Waste Management (SWM) and Technical Assistance and Training (TAT) grants to improve planning and management of solid waste sites in rural areas. In the business sector, National Waste Management Holdings (OTC: NWMH), a solid waste management company, has been steadily expanding its influence across the East Coast with an aggressive acquisition strategy that is bringing more and more facilities under its wing. The company’s comprehensive waste management approach includes an array of landfill disposal services, roll off containers for rental, and a line of recycled wood and garden mulch.

In a recent, exclusive audio interview (http://dtn.fm/7Yj2m) with NetworkNewsWire, a multifaceted financial news and publishing company, National Waste Management Holdings CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor spoke toward a few of the company’s 2017 acquisition goals. A recent article cites a paper shredding facility in New York as being under consideration, and that acquisition would open NWMH to a sizable market in the region. As it stands, NWMH already services residential and commercial customers in Upstate New York, as well as in its home state of Florida.

An article (http://dtn.fm/8tRw2) from the Proceedings of the National Academy of Sciences of the United States of America found, upon examining the world’s megacities, that New York exceeds the rest in solid waste production, both in absolute and per capita terms. In addition, despite Tokyo being the largest megacity by population, New York surpasses it in terms of energy consumption of both transportation fuels and heating/industrial fuels. The article also states that New York consumes the energy of approximately two megacities; the equivalent of approximately one supertanker every 1.5 days. Interestingly, statistics in the 2014 Tables and Figures (http://dtn.fm/iWhx3) published by the EPA last month show that the Northeast more than doubles the rest of the nation in terms of municipal waste-to-energy capacity, with nearly 800 tons/day throughput per million people. Resource recovery facilities can turn solid waste into vital energy. One such facility, for example, is the Essex County Resource Recovery Facility that processed 2,800 tons of municipal solid waste per day in 2012 between its two generators, producing approximately 65 megawatts of energy.

While the Northeast led in terms of waste-to-energy capacity as well as estimated MRF throughput in 2014, it had, by far, the least number of landfills in the U.S., per the EPA report, potentially signifying a largely untapped market. SaveOnEnergy.com notes (http://dtn.fm/IebN2) that New York is the largest giver of trash to Ohio, accounting for nearly 32 percent of the state’s out-of-state total, with New Jersey coming in close behind. National Waste Management Holding’s initial acquisition strategies on the East Coast are part of the company’s larger objective of national expansion.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board